• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Bear Charts of the Day: Eli Lilly, Ventas

Today may be a good opportunity to exit some names.
By TIMOTHY COLLINS
Aug 25, 2015 | 09:03 AM EDT
Stocks quotes in this article: LLY, VTR

And just like that, most of the pain from yesterday is gone. The media is calling it another Black Monday, but it was Grey Monday, at worst.

The widespread sell off hit every sector. Nothing was spared. Today's bounce may set up the opportunity to exit some names, or even look short.

Even some of the stronger, more conservative names fell yesterday. Eli Lilly (LLY) was among that group.

A large gap down, which was common everywhere, was met with little bounce comparatively. The stock closed not far off its low and never gave a real shot at filling its gap.

After the July drop, the rise in August looks more like a bear flag now, with a false breakout attached to its end.

There is a double top in place right above $88, although that feels like forever away from the current price.

Neutral and bullish setups in the Relative Strength Index (RSI), moving average convergence divergence (MACD), Ultra Index, and Commodity Channel Index (CCI), have all turned bearish.

While this is common place now on many daily charts, I think it is a good marker to watch what stocks bounce back into resistance today, fail to break through it and do not see at least two indicators get back to a neutral position.

LLY needs to get back over $82 minimum for a somewhat neutral setup, but really needs to be over $83.70 to provide any interest other than exiting or shorting for me.

Ventas (VTR) was strong going into yesterday, even with last week's selloff. The stock fell through two different levels of support, both bullish channel patterns.

The stop has been riding the 10-day simple moving average (SMA), which created the first level of support. The second level, at $58, was also broken.

A third level around the 50-day SMA did come into play around the close of the day, so it is worth watching.

We also saw multiple technical indicators go from bullish to bearish in a single day. The RSI, CCI, Ultra Index and MACD all saw bearish crossovers.

I would pay close attention today and note if they reverse. The other area I am watching is price. A close over $58, but under $59 puts us back in the channel and is somewhat neutral.

A rejection off $59 with a close under $58 should set us up for more downside, especially if we don't see at least two of those indicators flip back in favor of the bulls.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Timothy Collins had no positions in the stocks mentioned.

TAGS: Investing | U.S. Equity | Stocks

More from Investing

Marveling at the Market's Move? It's All About Momentum

James "Rev Shark" DePorre
Jan 19, 2021 4:41 PM EST

No news can explain the action -- whether the bears believe it or not.

Surface Oncology Is Set for Further Gains - How to Buy It

Bruce Kamich
Jan 19, 2021 3:25 PM EST

Here's our price objective.

My Preference With OneSpan Is Calls So I Can Define My Risk

Timothy Collins
Jan 19, 2021 2:36 PM EST

The last few post-earnings beat downs were greeted with optimism once traders got over the initial disappointment.

A Top Biotechnology Play for 2021

James "Rev Shark" DePorre
Jan 19, 2021 2:07 PM EST

Forte's sole clinic candidate is FB-401 for the treatment of atopic dermatitis, which is the scientific name for eczema.

Boot Barn Gets a Quant Upgrade: Do the Charts Fit?

Bruce Kamich
Jan 19, 2021 1:53 PM EST

Here's our latest analysis and trading strategy for the shares.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:09 AM EST GARY BERMAN

    Is Copper About to Turn to Rust?

    Below is a very long-term copper chart.  As you...
  • 08:02 AM EST GARY BERMAN

    Tuesday Morning Fibocall for for 1/19/2021

    SPX (Long-Term View) The 1/8/21 high @ 3826.69 i...
  • 09:01 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    When it's time to sell, will you act or freeze?
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login